Table of Contents

• Immunotherapies to Nano-Immunotherapies: Advances in Immune Targeting in Bladder Cancer

  Beatriz Ramos, Dakota Rogers

  Bladder cancer is among most common malignancies worldwide, with significant morbidity and mortality. Conventional treatment strategies for bladder cancer include transurethral resection, radical cystectomy and chemotherapy. However, the complex immune landscape of bladder cancer involves innate and adaptive immune components that either promote or suppress tumor progression. Upregulation of check...

  REVIEW | Published: 05 Feb 2025

  Annals of Urologic Oncology, Volume 8 (2025), Issue 1

  Pages: 1-11   PDF(1670KB)   Views：232Downloads：2

• Advancements in Research on Non-AR- Signaling Pathways and Targeted Therapies for Castration-Resistant Prostate Cancer

  Haq Dad, Asger Hansen

  Prostate cancer (Pca) is a significant malignancy affecting men's health, with its incidence steadily increasing worldwide in recent years. Among its various subtypes, castration-resistant prostate cancer (CRPC) holds particular importance due to its pivotal role in the progression and management of Pca. The treatment options for Pca range from surgery to medication. However, the mechanisms underl...

  REVIEW | Published: 27 Dec 2024

  Annals of Urologic Oncology, Volume 8 (2025), Issue 1

  Pages: 12-20   PDF(1200KB)   Views：263Downloads：5

• Advances in Illuminating Prostate Cancer with Emerging Phototherapies

  Ali Usman

  Prostate cancer is a worldwide health concern in men, with substantially high incidence rate and advanced metastatic disease-related mortality rates. Despite advancements in diagnostics and treatment options, conventional therapies for prostate cancer, including surgery, radiotherapy, chemotherapy and androgen deprivation therapy, face limitations such as treatment resistance, limited precision an...

  REVIEW | Published: 31 Jan 2025

  Annals of Urologic Oncology, Volume 8 (2025), Issue 1

  Pages: 21-29   PDF(2220KB)   Views：328Downloads：5

• A Potential Role of MicroRNA in the Renal Cancer and Its Tumor Microenvironment

  Daniel Chikere Ali, Siva Bharath Merugu

  Renal cell carcinoma (RCC) accounts for approximately 2.2% of all diagnosed cancers and 1.8% of cancer-related deaths. Clear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of RCC, accounting for approximately 70–80% of all cases. Despite significant advancements in therapeutic strategies over recent decades, treatment outcomes for ccRCC patients remain suboptimal. Prognosis for in...

  REVIEW | Published: 29 Jan 2025

  Annals of Urologic Oncology, Volume 8 (2025), Issue 1

  Pages: 30-39   PDF(1930KB)   Views：236Downloads：4

• Metabolic Supremacy Fuels Tumor Aggressiveness in Renal Cancer

  Reham Gholam, Muhammad Khalilzad

  Renal cell carcinoma, with clear cell renal carcinoma (ccRCC) being the dominant form, is recognized as a malignancy driven by abnormal metabolic processes, with extensive alterations in glucose, lipid, and amino acid pathways. The loss of the Von Hippel-Lindau (VHL) gene in nearly 90% of ccRCC instances results in the accumulation of hypoxia-inducible factors (HIFs), producing a pseudo-hypoxic en...

  REVIEW | Published: 02 Mar 2025

  Annals of Urologic Oncology, Volume 8 (2025), Issue 1

  Pages: 40-49   PDF(1910KB)   Views：160Downloads：3

• Involvement of Epidermal Growth Factor Receptor (EGFR) Signaling in Renal Cell Carcinoma Progression and Therapeutic Implication

  Ghulam Raza, Kareem Khan

  Renal cell carcinoma (RCC) is the common type of kidney cancer linked to alteration of lipid, glucose, and amino acid metabolism. Early stage RCC has prognosis with overall 5-year survival rate of 90%, and the RCC has unfavorable prognosis when the disease metastasizes. Loss of or carrying mutated tumor suppressor gene VHL is the cause of HIF elevation leading to initiation of RCC. The epidermal g...

  REVIEW | Published: 23 Mar 2025

  Annals of Urologic Oncology, Volume 8 (2025), Issue 1

  Pages: 50-58   PDF(1125KB)   Views：51Downloads：2

• Reliability and Preliminary Validation of a Body Image Scale Survey for Use in Bladder Cancer Patients

  Ava Saidian, Hannah G Hingtgen ... Amirali Salmasi

  Extirpative bladder surgery for bladder cancer requires urinary diversion which causes cosmetic and functional changes that affect a patient’s body image and quality of life. Current health-related quality of life (HRQOL) surveys validated for use in bladder cancer patients have no dedicated domain evaluating body image. We sought to validate the ten-item Body Image Scale (BIS) for use in bladder ...

  RESEARCH | Published: 13 Oct 2024

  Annals of Urologic Oncology, Volume 7 (2024), Issue 4

  Pages: 143-147   PDF(448KB)   Views：416Downloads：15

• Basic Study on Gene Biology of Bladder Cancer Metastasis

  Clara Joseph

  Bladder cancer is a complex disease with distinct treatment approaches based on its progression. For non-muscle invasive bladder cancer, the primary treatment method involves complete tumor resection, followed by immunotherapy, intravesical chemotherapy, and regular monitoring. In cases of muscle-invasive bladder cancer, a multimodal approach-including radical cystectomy and neoadjuvant chemother...

  REVIEW | Published: 13 Nov 2024

  Annals of Urologic Oncology, Volume 7 (2024), Issue 4

  Pages: 148-157   PDF(1090KB)   Views：297Downloads：11

• The Role of Urinary Extracellular Vesicles in Kidney Cancer: Diagnostic and Therapeutic Potential

  Kirk Gallego

  Renal cancer ranks as the 14th most common cancer globally, with renal cell carcinoma (RCC) being the primary variant, arising from renal tubular epithelial cells; clear cell RCC constitutes about 80% of cases. Despite their limitations, surgery and targeted therapy remain the mainstays of RCC treatment. Regardless of advancements in RCC research, substantial obstacles continue to exist, such as d...

  REVIEW | Published: 17 Nov 2024

  Annals of Urologic Oncology, Volume 7 (2024), Issue 4

  Pages: 158-167   PDF(2050KB)   Views：315Downloads：14

• Advances in Prostate Cancer Immunotherapy: Current Options and Emerging Novel Approaches

  Nasser S Alanazi, Mohammed H Alrafiah

  Prostate cancer (PCa) is a significant malignancy in men, contributing considerably to the rise in male mortality rates worldwide. Men diagnosed with PCa may have either localized or advanced stages of the disease. Globally, it ranks as the second most common and fifth most aggressive cancer type in males. The likelihood of developing prostate cancer in a man’s lifetime is approximately one in sev...

  REVIEW | Published: 26 Oct 2024

  Annals of Urologic Oncology, Volume 7 (2024), Issue 4

  Pages: 168-176   PDF(1310KB)   Views：419Downloads：13

• Research Progress of AR Gene Family in Prostate Cancer Therapy

  Maham Khan

  Prostate cancer (PCa) is a malignancy originating from the epithelial cells of the prostate gland, strongly influenced by androgens, and is one of the most common cancers in men. Androgen deprivation therapy (ADT) is the primary treatment for prostate cancer. However, after prolonged ADT treatment, nearly all patients experience an increase in prostate-specific antigen (PSA) levels and tumor regro...

  REVIEW | Published: 18 Oct 2024

  Annals of Urologic Oncology, Volume 7 (2024), Issue 4

  Pages: 177-184   PDF(1120KB)   Views：385Downloads：11

• Role of Hyperbaric Oxygen Therapy in Prostate Tumor Microenvironment and Cancer Stem Cell Niche

  Pranathi Konda, Merrel Holley, Vinoth Kumar Lakshmanan

  Hyperbaric oxygen therapy (HBOT), has gained attention in recent years as a potential adjunct to conventional cancer treatments, particularly in addressing tumor hypoxia which is extensively employed as a post-injury treatment, is the administration of >92% oxygen at 1.5- 3.0 ATA for 60-120 minutes. HBOT is attributed to at least five mechanisms including epigenetic regulation of gene expression, ...

  REVIEW | Published: 12 Dec 2024

  Annals of Urologic Oncology, Volume 7 (2024), Issue 4

  Pages: 185-194   PDF(1698KB)   Views：963Downloads：27

• Glutamine Metabolism in Prostate Cancer

  Xuguang Guo

  Prostate cancer (PCa) is the most common malignancy in the urinary system. Research suggest that prostate cancer is often accompanied by gene mutations and metabolic reprogramming during disease progression, leading to disease advancement, metastasis, and therapeutic resistance. During metabolic reprogramming, glutamine serves as a carbon and nitrogen source to replenish the tricarboxylic acid cyc...

  REVIEW | Published: 04 Aug 2024

  Annals of Urologic Oncology, Volume 7 (2024), Issue 3

  Pages: 83-89   PDF(1230KB)   Views：710Downloads：17

• Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Dedifferentiation: Clinico Pathological Significance- Review

  Sunil V. Jagtap, Shubham S. Jagtap ... Devika Borade

  Sarcomatoid and/or rhabdoid dedifferentiation are rare histopathological findings which may be heterogeneous in renal cell carcinoma. Sarcomatoid renal cell carcinoma shows marked cytologic atypia and containing enlarged pleomorphic and malignant spindle cells reminiscent of sarcoma. It is highly aggressive with a high metastatic potential and extremely poor prognosis. ...

  REVIEW | Published: 27 Aug 2024

  Annals of Urologic Oncology, Volume 7 (2024), Issue 3

  Pages: 90-96   PDF(1900KB)   Views：3358Downloads：44

• Treatment Strategies for BCG Unresponsive Non-muscle Invasive Bladder Cancer

  Anusha Gupta, Shiv Verma, Sanjay Gupta

  Bacillus Calmette-Guérin (BCG) is the standard treatment for patients with non-muscle invasive bladder cancer (NMIBC). Although this therapy has been effective, BCG resistance poses a significant challenge, highlighting the need for alternative treatment options. Possible alternative treatments include intravesical chemotherapy, immunotherapy, antibody-drug conjugates, device-assisted therapies, g...

  REVIEW | Published: 29 Aug 2024

  Annals of Urologic Oncology, Volume 7 (2024), Issue 3

  Pages: 97-109   PDF(957KB)   Views：783Downloads：34

• Research Progress of Neoadjuvant Chemotherapy in Advanced Bladder Cancer

  Haijun Hu, Xianghui Wu

  Systemic treatment, commonly referred to as chemotherapy, is a fundamental approach for treating muscle-invasive bladder cancer (MIBC) and metastatic bladder cancer. Neoadjuvant chemotherapy has recently become a standard treatment for MIBC, significantly reducing tumor recurrence rates and improving patient outcomes. Patients may receive adjuvant chemotherapy involving various drug combinations t...

  REVIEW | Published: 09 Sep 2024

  Annals of Urologic Oncology, Volume 7 (2024), Issue 3

  Pages: 110-117   PDF(718KB)   Views：408Downloads：11

• Molecular and Clinicopathological Correlates of Wild-Type KRAS Expression in Prostate Cancer

  Henry O. Ebili, Sebastian A. Omenai ... Ngozi Chidozie

  The clinicopathological significance of KRAS alterations in clinical prostate cancer (PCa) has yet to be comprehensively studied, and the classic KRAS somatic mutations are rare in PCa. The clinico-genomic data of two PCa cohorts were retrieved from the cancer genome databases. KRAS expression-based gene enrichment for cell proliferation, apoptosis, and epithelial-mesenchymal transition /invasion ...

  RESEARCH | Published: 31 Jul 2024

  Annals of Urologic Oncology, Volume 7 (2024), Issue 3

  Pages: 118-131   PDF(2470KB)   Views：715Downloads：16

• Comparative Analysis of PSA Nadir and Time to PSA Nadir on Clinical Outcomes in Patients with De Novo Spine Metastasis of Prostate Cancer Undergoing Androgen Deprivation Treatment (ADT) Only vs. ADT Intensification

  TAGANG Titus NGWA-EBOGO, Landry Oriol MBOUCHE ... Fru Forbuzshi ANGWAFO III

  Metastatic prostate cancer, particularly with bone involvement, is a severe form of the disease associated with poor prognosis. Androgen deprivation therapy (ADT) has been the standard treatment, but recent strategies suggest that ADT intensification may improve outcomes. This study evaluates the impact of ADT intensification on prostate-specific antigen (PSA) Nadir, time to PSA Nadir, and clinica...

  RESEARCH | Published: 16 Aug 2024

  Annals of Urologic Oncology, Volume 7 (2024), Issue 3

  Pages: 132-142   PDF(1056KB)   Views：558Downloads：13

• Research Progress on the Association between Obesity and Prostate Cancer

  Hang Xu, Yingshuang Tang ... Along Kang

  The complex association between obesity and prostate cancer necessitates exploring how obesity impacts the incidence, progression, treatment response, and prognosis of prostate cancer. An analysis was conducted to determine the potential adverse effects of obesity on prostate cancer treatment, including changes in drug metabolism and surgical complications. It also discusses how obesity increases ...

  REVIEW | Published: 18 Jul 2024

  Annals of Urologic Oncology, Volume 7 (2024), Issue 2

  Pages: 48-54   PDF(686KB)   Views：692Downloads：15

• Clinical Features and Significance of Malignant Priapism

  Dilibe C. Ekowa, Austin J. Marrah ... Yujiang Fang

  Priapism is a disorder defined as a persistent erection maintained without an appropriate sexual stimulus lasting for longer than 4 hours. Priapism is generally classified into two categories, ischemic and non-ischemic. Ischemic priapism is considered a true urological emergency as prolongation of this subtype is often associated with loss of sinusoidal endothelial function, corporal fibrosis, and...

  REVIEW | Published: 18 Jul 2024

  Annals of Urologic Oncology, Volume 7 (2024), Issue 2

  Pages: 55-60   PDF(1056KB)   Views：542Downloads：11